4 周大的婴儿可以安全地使用 Ivacaftor（Kalydeko）治疗囊性纤维化，扩大了治疗选择。 4-week-old infants can safely use Ivacaftor (Kalydeko) for cystic fibrosis, expanding treatment options.
一项新研究表明，囊性纤维化药物 Ivacaftor (Kalydeko) 对四周及以上的新生儿是安全有效的。 A new study indicates that a cystic fibrosis drug, Ivacaftor (Kalydeko), is safe and effective for newborn babies aged four weeks and above. 这标志着囊性纤维化治疗的重大突破，为婴儿早期干预开辟了可能性。 This marks a significant breakthrough in Cystic Fibrosis treatment, opening up earlier intervention possibilities for infants. 目前，该药物被批准用于四个月及以上的婴儿，但新的研究表明，它对四周大的婴儿也有效。 Currently, the drug is approved for use in babies aged four months and older, but the new research suggests it can also be effective for infants as young as four weeks.